Dr. Jarell discusses a recently presented poster,¹ on which he served as an investigator, which reported results of a retrospective analysis conducted in a cohort of patients (N=1,662) with stage I–II cutaneous melanoma who had been clinically tested with the 31-gene expression profile (GEP) test to determine the association of central nervous system metastasis with the 31-GEP test result. View the full abstract here.
Reference:
-
Hasanov M, Martin B, Hasanov E, et al. he 31-GEP identifies patients with localized cutaneous melanoma at the highest risk of metastasis to the central nervous system. Presented at: EADO 2025; April 3–5, 2025, Athens, Greece.
Disclosures: Dr. Jarell has served as an investigator, consultant, and speaker for Castle Biosciences.
